

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has noted the recent unusual fluctuation in the price and trading volume movements of the shares of the Company (the “**Shares**”) in the past two days. Having made all such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that, save as published on February 16, 2024, the Company is removed as a constituent stock on the Hang Seng Composite Index and with effect from March 4, 2024, the Company is no longer included on the Hong Kong Stock Connect, it is not aware of any other reasons for the fluctuations in the price and trading volume of the Shares, or any information that must be published to avoid a false market in the Company’s securities, or any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company wishes to clarify that all current business development and operation of the Company remains normal. As of the date of this announcement, the Company is not aware of any change in the regulatory regime which may result in material negative impact on the business operations of the Group and, domestic or international clinical trial approvals in the future. Additional information concerning the Company’s business operations and financial position will be available in the Company’s annual results announcement, which is scheduled to be published in late March 2024, and in an investor presentation which the Company intends to convene following the publication of the annual results announcement.

The Company wishes to remind the Company’s shareholders and potential investors to rationally treat any information not officially published by the Company, and the Company’s shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, March 5, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.